This study focused on investigating whether Tan-IIA can inhibit HCC progression by modulating METTL3- and METTL14-dependent M6A modifications, which might contribute to exploiting more effective therapeutic strategies for HCC. The gene discussed is METTL3; the disease is hepatocellular carcinoma.